Latest Hotspot

Nektar Therapeutics Reports Encouraging Preliminary Results from Phase 1b Trial of Rezpegaldesleukin

20 September 2023
3 min read

Nektar Therapeutics disclosed fresh clinical results concerning rezpegaldesleukin utilised for patients battling atopic dermatitis, featuring new clinical effectiveness parameters from its Phase 1b research. Rezpegaldesleukin represents Nektar's innovative, unprecedented selective regulatory T-cell therapy, currently under development for managing atopic dermatitis.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

Nektar Therapeutics is showcasing the fresh Phase 1b clinical efficacy endpoints for rezpegaldesleukin. The latest data underscore the significant potential of rezpegaldesleukin in providing relief to those suffering from atopic dermatitis, a skin disorder affecting roughly 10% of the US population. Furthermore, details concerning the trial formats for their upcoming Phase 2b study of rezpegaldesleukin in atopic dermatitis, kicking off in October, along with a newly proposed Phase 2a study commencing early 2024 in alopecia areata will also be shared.

"Today's release of new findings relating to rezpegaldesleukin in atopic dermatitis confirms rezpegaldesleukin's potential as a unique therapeutic that could significantly enhance the lives of patients. This is besides the powerful efficacy already reported for EASI-related endpoints," commented Nektar Therapeutics' Chief R&D Officer, Jonathan Zalevsky, Ph.D.

"We eagerly anticipate proceeding with rezpegaldesleukin into our comprehensive Phase 2b study involving biologic-naïve patients living with moderate to severe atopic dermatitis by October this year. We're thrilled to also share news of a Phase 2a study commencing in 2024, set to explore the use of rezpegaldesleukin in treating patients with alopecia areata," Zalevsky added.

The double-blind, placebo-controlled Phase 1b study on rezpegaldesleukin's application in atopic dermatitis was conducted to determine its safety, tolerance, and pharmacokinetics over a 12-week induction treatment period. Patients who met the EASI-50 response at Week 19 were monitored for an additional 36 weeks post-treatment or until they no longer met the EASI-25 response criteria. The initial study analyzed 44 patients with moderate-to-severe AtD who had not responded to topical corticosteroids.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 18, 2023, there are 21 investigational drugs for the IL-2Rβ target, including 14 indications,18 R&D institutions involved, with related clinical trials reaching 23and as many as 2976 patents.

Rezpegaldesleukin is a cytokine fusion protein drug that targets IL-2Rβ. It is being developed for the treatment of immune system diseases, congenital disorders, and skin and musculoskeletal diseases. The drug has reached Phase 2 of clinical development globally and is currently at the IND application stage in China. 

图形用户界面, 文本

描述已自动生成

Review and Prospects of HDAC Inhibitors
Review and Prospects of HDAC Inhibitors
20 September 2023
HDAC (Histone Deacetylase), otherwise known as a histone deacetylase, is an important type of enzyme involved in the process of histone modifications.
Read →
Coeptis Therapeutics provides update on DVX201's Phase 1 Trials safety and dosage for Relapsed/Refractory AML or High Risk MDS patients
Latest Hotspot
3 min read
Coeptis Therapeutics provides update on DVX201's Phase 1 Trials safety and dosage for Relapsed/Refractory AML or High Risk MDS patients
20 September 2023
Coeptis Therapeutics delivers an update on the safety and dosage from Phase 1 Trials of DVX201, intended for those with Relapsed/Refractory AML or High Risk MDS.
Read →
Progress in the Research of GnRHR Agonists
Progress in the Research of GnRHR Agonists
20 September 2023
GnRHR, or Gonadotropin-Releasing Hormone Receptor, plays a crucial role in the human body's reproductive system.
Read →
Alzheon Announces Clinical Advances Therapy in Phase 2 Study of ALZ-801  Administered Orally to Early Alzheimer's Patients
Latest Hotspot
4 min read
Alzheon Announces Clinical Advances Therapy in Phase 2 Study of ALZ-801 Administered Orally to Early Alzheimer's Patients
20 September 2023
Alzheon, Inc. reported that their Phase 2 study of ALZ-801 resulted in reduced neural degradation, stabilized brain function, and improved cognition in initial Alzheimer's patients with the apolipoprotein ε4 allele over two years of treatment.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.